CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02655770
NCT02655770Phase 4Completed
CompareCT.gov

Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial

Rigshospitalet, Denmark·interventional·Posted Jan 14, 2016·Updated Jan 14, 2021

In Brief

A Phase 4 clinical trial evaluating Liraglutide and Placebo for Diabetes Mellitus Type 2 and 3 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion
CountriesDenmark
CollaboratorsSlagelse Hospital, Novo Nordisk A/S

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 14, 2016
Enrollment StartFeb 1, 2016
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.5 years ago

Interventions

Liraglutidedrug

Placebodrug